4Kim SI, Kim HJ, Han DC ,et al. Effect of lovastatin on small GTPbing proteins and on TGF-beta1 and fibronectin expression [ J ]. Kidney Int Suppl, 2000, 77: S88-92.
1Kelly DJ, Stein-Oakley A, Zhang Y, et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2) 27 rats: attenuation with renin-angiotensin blockade. Nephrology,2004, 9: 7-13.
2Locatelli F, Canaud B, Eckardt KU, et al.The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant, 2003, 18: 1716-1725.
3Keane WF, Lyle PA. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis, 2003, 41 Suppl 1: S22-S25.
4American Diabetes Association. Nephropathy in Diabetes. Diabetes Care, 2004, 27Suppl 1: S79-S83.
5Laverman GD, Remuzzi G, Ruggenenti P.ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol, 2004, 15: S64-S70.
6Deferrari G, Ravera M, Berruti V, et al.Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J Am Soc Nephrol, 2004, 15:S6-S11.
7Prisant LM. Diabetes mellitus and hypertension: a mandate for intense treatment according to new guidelines. Am J Ther, 2003, 10: 363-369.
8Berl T. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J Am Soc Nephrol, 2004, 15:S71-S76.
9Rossing K, Pietraszek L, Jacobsen P, et al. Renoprotective effects of adding angiotensin Ⅱ receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care,2003, 26: 2268-2274.
10Tuttle KR. Linking metablism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol,2005; 16 (6): 1537-1538.
